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HIV has become one of the most devastating pathogens in human history. Despite fast progress in HIV-related
basic research, antiretroviral therapy (ART) remains the most effective method to save AIDS patients’ lives.
Unfortunately, ART cannot be universally accessed, especially in developing countries, due to the lack of
effective treatmentmonitoring diagnostics. Here, we present an inexpensive, rapid and portablemicro-a-fluidic
platform, which can streamline the process of an enzyme-linked immunosorbent assay (ELISA) in a fully
automated manner for CD4 cell count. The micro-a-fluidic CD4 cell count is achieved by eliminating
operational fluid flow via ‘‘moving the substrate’’, as opposed to ‘‘flowing liquid’’ in traditional ELISA or
microfluidic methods. This is the first demonstration of capturing and detecting cells from unprocessed whole
blood using the enzyme-linked immunosorbent assay (ELISA) in a microfluidic channel. Combined with cell
phone imaging, the presented micro-a-fluidic ELISA platform holds great promise for offering rapid CD4 cell
count to scale upmuch needed ART in resource-constrained settings. The developed system can be extended to
multiple areas for ELISA-related assays.
H
IV has significantly impacted basic and clinical research for better patient care by causing more than 25
million deaths and 35.3 million people infected worldwide1. Although antiretroviral therapy (ART) is
effective in saving AIDS patients’ lives, the implementation of ART worldwide has been drastically ham-
pered by the lack of treatment monitoring diagnostics. According toWHO 2013 guidelines, the coverage of ART is
still only 34% in low- and middle-income countries1, despite ART being affordable or even free. The fundamental
challenge is that AIDS patients on ART need to be closely monitored for drug adherence and efficacy, but existing
viral load and CD4 cell count assays generally remain costly and technologically complex2. In addition, these
monitoring diagnostics cannot be implemented in rural areas where basic laboratory infrastructure and trained
operators are lacking. Thus, a point-of-care (POC) diagnostic tool is highly desirable to deliver treatment mon-
itoring to AIDS patients wherever and whenever needed.
Microfluidics have been widely utilized to develop POC diagnostics and thus to address global healthcare
issues, including HIV3,4. However, the requirement for precise control of fluid flow often dictates the need for
bulky, expensive instruments and well-trained operators, which significantly impedes the translation of micro-
fluidic technologies into clinical practice5,6. Researchers, for example, need to achieve fine manipulation of
different fluids in terms of when, where and how much for accurate measurements in a multiple-step biological
reaction process such as ELISA. The hidden cost and complexity associated with precise fluid flow constitute a
critical barrier for performing microfluidic-based diagnosis at the POC. The complex designs required to pre-
cisely control fluid flow in microfluidic devices (e.g., addition of valves) are generally not yet amenable to
automation for POC testing7. Moreover, the generation of air bubbles in flow-based microfluidics devices due
to switching of liquid reagents can potentially block microchannels, thus compromising or even disabling
targeted biological reactions. Hence, the development of flow-free, bubble-free, portable devices is a pre-requisite
to perform simple, rapid and inexpensive ART monitoring at the POC.
Herein, we developed a micro-a-fluidic ELISA (m-ELISA) to rapidly measure CD4 cell count in an automated
manner. This process is initiated by m-ELISA and concluded with a cell phone-based colorimetric detection
(Fig. 1a). In the micro-a-fluidic system, fluids are stationary, while the captured CD41 T lymphocytes are mobile.
We demonstrated the unique capability of m-ELISA to capture and detect cells from whole blood without sample
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processing (e.g., cell fixing), which cannot be achieved in traditional
flow-based ELISA due to high shear stress. The m-ELISA detected
down to 30 CD41 T lymphocytes per reaction in a total assay time of
9 minutes. Among the unprocessed whole blood samples of 35
patients, the m-ELISA assay measured CD41 T cell counts with an
accuracy of 97% at the clinical cutoff (e.g., 350 cells/mL) recom-
mended by the World Health Organization (WHO)20 for prioritiz-
ing ART, thus offering a ‘‘plug-and-play’’ solution to the scale-up of
ART in AIDS patients in resource-constrained settings.
Results
Working principle of micro-a-fluidic ELISA. The m-ELISA elimi-
nates fluid flow by ‘‘moving the substrate’’ through different aqueous
phases, in contrast to ‘‘flowing liquid’’ through a microwell or
microchannel as performed in the traditional flow-based ELISA.
The temporal processes such as sample incubation, washing,
enzyme labeling, and colorimetrical detection were performed
spatially via manipulating magnetic beads in a micro-a-fluidic
device (Fig. 1b). Five circular chambers were separately pre-loaded
with whole blood plus antibody-functionalized magnetic bead, wash
buffer, horseradish peroxidase (HRP)-conjugated antibody, wash
buffer and 3,39,5,59-tetramethylbenzidine (TMB) solution. The 5
elliptical chambers located between the circular chambers
contained mineral oil for physical phase separation of reagents.
Mineral oil physically separated the aqueous solutions within the
circular chambers while still allowing for the transmission of the
Figure 1 | Design of m-ELISA for CD41 T lymphocyte count. (a) Overview of the m-ELISA based chip platform. The testing process can be divided into
three steps consisting of sample collection, rapid cell-based m-ELISA, and cell phone based colorimetric detection. A droplet from a finger prick can be
collected and loaded onto a micro-a-fluidic chip along with antibody-functionalized magnetic beads. The micro-a-fluidic chip is placed on a permanent
magnet, which is fixed on amotorized stage.With the aid of a software program, the stage is used to control and complete the entire process of ELISA in an
automated manner. As a result, the color development on-chip is imaged using a cell phone and the result is analyzed using an integrated mobile
application. (b) Design of a micro-a-fluidic chip and cell-based CD4 ELISA. The chip is designed to contain five aqueous circular chambers (i, ii, iii and
two wash chambers containing phosphate buffered saline plus 0.5% tween 20 (PBST)) and five elliptical chambers containing mineral oil for physical
separation of the hydrophilic circular chamber liquids. In chamber i, functionalized magnetic beads conjugated with anti-CD4 antibody are used to
selectively capture cells (CD41 T lymphocytes and monocytes) expressing CD4 molecules on the surface. After a washing step in the intermediate
chamber, themagnetic beadswith capturedCD41 cells aremoved to chamber ii and taggedwith anti-CD3 antibody, which is conjugatedwith horseradish
peroxidase (HRP). After another wash, the captured CD41 T lymphocytes enable color development due to digestion of 3,39,5,59-Tetramethylbenzidine
(TMB) by HRP in chamber iii. The photograph in (a) was taken by ShuQi Wang.
www.nature.com/scientificreports
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CD41 cell-magnetic bead complexes. In the first circular chamber,
magnetic beads functionalized with anti-CD4 antibody were used to
capture CD41 cells from whole blood. The magnetic beads carrying
captured CD41 cells were then washed in the second circular
chamber to remove unbound, non-specifically attached cells. In
the third circular chamber, HRP-conjugated anti-CD3 antibody
was tagged onto the captured CD41 cells. After another wash in
the fourth chamber, the HRP-tagged CD41 cells induced the
oxidation of TMB and generated blue color in the fifth chamber.
The color intensity was quantified using a smart phone with an
integrated mobile application8. The entire ELISA process was
automated to complete within 9 minutes using an in-house-
developed portable magnetic actuator (Supplementary Fig. 1).
Characterization of CD41 cell capture onmagnetic beads.Charac-
terization of the capture of CD41 cells on magnetic beads that were
functionalized with anti-CD4 antibody, was carried out using
immunostaining and scanning electron microscopy (SEM). In
Fig. 2a, a CD41 T lymphocyte (both CD3 and CD4 positive) was
captured on a magnetic bead and stained using Alexa 488-labeled
anti-CD4 antibody emitting green fluorescence. Since monocytes
express CD4 molecules (but not CD3 molecules), monocytes can
also be captured on the beads. To differentiate the emission of
CD41 T lymphocytes from monocytes, we used Alexa 647-labeled
anti-CD3 antibody (Fig. 2a). This antibody does not stain
monocytes, but binds to CD41 T lymphocytes. The overlaid
fluorescence micrographs showing the emission of Alexa 488 and
647, as well as the bright field and SEM images confirm the capture of
CD41 T lymphocytes on magnetic beads (Fig. 2a). The capture
efficiency of CD41 T lymphocytes on magnetic beads was analyzed
also by means of flow cytometry. The results showed that the capture
efficiency was 68 6 4% over incubation times varying from 1 to
10 min, and there was no statistically significant difference in
capture efficiency among the varying incubation times (p . 0.05,
n 5 3) (Fig. 2b). These data with confidence indicate that CD41 T
lymphocytes were captured on magnetic beads by anti-CD4
antibodies in a few minutes. In addition, we evaluated the capture
efficiency over the decreasing concentrations of CD41 T
lymphocytes (Fig. 2c). The highest capture efficiency was 69 6
3.6% for 1,200 cells/mL; the lowest capture efficiency was 60.3 6
6.0% for 50 cells/mL. One-way ANOVA analysis indicated that
there was no statistically significant difference in capture efficiency
over the concentrations of CD41 T lymphocytes ranging from 50–
1200 cells/mL.
Development of the protocol of micro-a-fluidic ELISA for CD4
cell count. We further developed a rapid protocol of m-ELISA for
quantification of CD41 T lymphocytes. To differentiate CD41 T
lymphocytes from monocytes, we used anti-CD3 antibody to
eliminate potential contaminant of monocytes, which also have
CD4 molecules on the cell membrane. We first evaluated various
concentrations of HRP-conjugated anti-CD3 antibody (151,000,
1510,000, 1580,000, 15100,000 and 151,000,000 dilutions from
stock concentration) in m-ELISA to reduce the background
readout. In these experiments, a plasma sample was used as a
negative control, where a whole blood sample was used as a
positive control for CD4 cell count. The results showed that
1580,000 dilution of anti-CD3-HRP antibody only developed
slightly, close to negligible blue color with a normalized R-value of
0.03 (Fig. 2d). We chose the 1580,000 dilution of anti-CD3-HRP
antibody as a working concentration (0.52 ng/mL) in the following
experiments, as it also elicited sufficient color development in
positive samples as opposed to the dilutions of 15100,000 and
151,000,000. We then evaluated the impact of TMB incubation
time on color development (Fig. 2e). The standard curve with a
5 min TMB incubation gave a better fit (R2 5 0.98) compared to
other incubation durations evaluated. Comparatively, longer incuba-
tion duration (10 min) led to saturation of color development
and shorter incubation (2 min) did not elicit sufficient color
development – neither of which would give accurate ELISA
quantification.
Modeling of magnetic forces in micro-a-fluidic devices. To better
understand the manipulation of magnetic beads in a micro-a-fluidic
device, we developed a computational model to evaluate magnetic
forces, fluidic drag forces, and interfacial forces on beads in a
magnetic field (Fig. 3). Based on the computational model, we
evaluated two magnetic forces: (i) magnetic forces that vertically
pull magnetic beads towards the base of the chamber (Fig. 3a), and
(ii) magnetic forces that pull beads parallel to the axis of the magnet
motion (Fig. 3b). Since the magnetic susceptibility of PMMA, water
and oil used in our experimental setup is much smaller (x= 1) than
that of magnetic beads (x? 1)9, the contribution to magnetic field is
negligible compared to magnetic beads, and thus we assume the
medium surrounding the magnet is uniform. The results showed
that as the distance between magnetic beads and the cylindrical
magnet underneath decreased, both vertical and horizontal
magnetic forces increased. Theoretically, if magnetic beads were
located above a critical height (h) from the surface of magnets,
magnetic forces exerted on beads would not be large enough to
overcome Brownian forces. To predict this limitation of our
design, we evaluated this height as a function of the magnetic bead
size. Critical height (h) for magnetic particles is calculated by Eq. 1–4
in the Supplementary Information, and plotted as a function of
radius of the bead in Fig. 3c. Results showed that with current
settings and parameters of the experimental setup, Brownian
motion is not effective in our experiments. Next, we calculated the
capillary pressure difference sustained across the interface between
mineral oil and PBS, and compared them with horizontal magnetic
forces (Fig. 3d). Since the shape of oil on-chip largely depends on the
elliptical chamber as shown in Fig. 1, although the elliptical shape of
oil changed slightly after testing, we used the shape of ellipsoid (b and
a are the major andminor radii) to calculate capillary pressure. Then
capillary pressure difference can be written DP~{c+Nbn~2cH,
where mean curvature, H(t) 5 ab/(b2cos2t 1 a2sin2t)3/2. Here, t 5
0 corresponds to points where ellipsoidal chambers are intersected
with themajor horizontal path of themagnetic beads. Then, capillary
pressure difference, DP 5 22ca/b2, where c is surface tension of
mineral oil against PBS (c 5 50 mN/m). In Fig. 3d, DP (Pa) are
plotted as a function of b/a (dashed blue line), and corresponding
shapes of chambers are also plotted in the figure. Magnetic forces (z
5 2 mm) per cross-section area of magnetic beads are plotted as a
function of r/R (solid red line). Results showed that as b/a ratio
decreases (or ellipsoidal chambers become more circular) capillary
pressure difference increases. We also plotted magnetic flux density
(contours) and unit magnetic forces (red arrows) when a magnet
moves horizontally from left to right (Fig. 3e, Supplementary Fig. 2a).
Validation of micro-a-fluidic ELISA for CD4 cell count. Finally,
we demonstrated that the accurate CD41 T lymphocyte counts by
means of m-ELISA was suitable for monitoring of antiretroviral
therapy in AIDS patients. We tested 17 AIDS patients and 18
transplantation patients with artificially suppressed immune
systems for CD41 T lymphocyte counts. Compared to the gold
standard for CD4 cell count, i.e., flow cytometry, m-ELISA results
showed a linearity of 0.86 (R2) and 0.90 (R2) in AIDS patients and
transplantation patients, respectively (Fig. 4a, b). In AIDS patients
without therapeutic intervention, the CD4 cell count generally tends
to be low. Since the samples were collected from AIDS patients who
were on treatment, the CD4 cell count of most patients exceeded the
clinical cutoff (350 cells/mL) recommended by the WHO for
prioritizing ART in resource-constrained settings20. The CD4 cell
count with m-ELISA ranged from 237 to 1,446 cells/mL in AIDS
patients and from 146 to 1,237 cells/mL in transplantation patients.
www.nature.com/scientificreports
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Figure 2 | Characterization of m-ELISA for CD4 cell count. (a) Capture of CD41 T lymphocytes (red arrow) onmagnetic beads (blue arrow). Magnetic
beads were incubated with whole blood and the captured T lymphocyte was stained with anti-CD4 Alexa Fluor 488 and anti-CD3 Alexa Fluor 647. The
fluorescent images of Fluor 488, Alexa Fluor 647, bright-field, as well as the overlaid image (by ImageJ software) demonstrate capture of CD41 T
lymphocytes by magnetic beads. The scanning electron microscope (SEM) image validates the capture of CD41 T lymphocyte on magnetic beads. The
scale bar is 10 mm. (b) Efficiency of magnetic beads for capturing CD41 T lymphocytes at varying incubation times. 25 mL of functionalized magnetic
beads (10 mg/mL)were incubatedwithwhole blood containing 1,000 cells/mLCD41T lymphocyte. The unboundT lymphocytes in the supernatant were
quantified by flow cytometry, which was used to calculate the capture efficiency. One-way ANOVA was performed to analyze and no statistical
significance (p. 0.05) was found. (c) Efficiency ofmagnetic beads for capturing CD41 T lymphocytes at varying concentrations of CD41 T lymphocytes.
The same procedure as mentioned in (b) was used to calculate the capture efficiency. One-way ANOVA analysis indicated that there was no significant
difference in capture efficiency (p . 0.05). (d) Optimization of HRP-antibody in m-ELISA. The variable, HRP-conjugated antibody was diluted at
different concentrations and tested with plasma samples, which served as negative control. 1580,000 was chosen for the following experiments since this
concentration was the highest concentration of HRP-antibody that avoided false positive results. A mobile application was used to extract red (R) pixel
values from the color development region on-chip and normalized them according to the background as shown in the Y-axis. One-way ANOVA
was performed to analyze the color intensity caused by excessive HRP (n 5 3, * indicates the statistical significance, p , 0.05). (e) Whole blood
from a healthy blood sample was serially diluted (undiluted, 153, 159, 1527 and 1581) used to construct the standard curve with different 3, 39, 5, 59
Tetramethylbenzidine (TMB) incubation periods. Each data point was performed in triplicates and the standard deviation was shown.
www.nature.com/scientificreports
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Further, we evaluated the discrepancy in CD4 cell count in both
populations measured by m-ELISA and flow cytometry (Fig. 4c, d).
Of 18 transplantation patients, only 1 sample had CD4 cell count
exceeding 61.96 S.D (Fig. 4e). Among 35 patients, m-ELISA had an
accuracy of 97.1% in identifying patients with CD4 cell count above
or below 350 cells/mL. These data demonstrate that the m-ELISA
platform can reliably report CD4 cell count for potential use in
monitoring ART in AIDS patients in resource-constrained settings.
Discussion
To the best of our knowledge, this report is the first demonstration
that cells can be reliably detected in ELISA in such a non-flow man-
ner. Because there is no fluid flow, cells can be captured on the
surfaces of magnetic beads without experiencing high shear stress,
which occurs in a conventional flow-based system. Due to high shear
stress generated in flow-based ELISA (i.e., multiple wash steps at high
speed), there is no report on the detection of cells attached to a solid
phase in amicrofluidic channel. It should be noted that cells could be
physically blocked and detected in filter-based microfluidic devices,
which allows for stringent washing and withstanding to resultant
high shear stress10. However, this flow-based ELISA strategy as
well as the use of fluorescence detection is not suitable for POC
testing according to the ASSURED criteria (i.e., affordable, sensitive,
specific, user-friendly, rapid, equipment-free and deliverable)11.
Figure 3 | Computationalmodeling of driving forces exerted onmagnetic beads. (a)Magnetic forces on a singlemagnetic bead in z-direction for a range
of vertical distance, z 5 1, 2, and 3 mm. (b) Magnetic forces on a single magnetic bead in r-direction. (c) Critical height (h), i.e., the location where
magnetic forces exerted on beads is comparable to Brownian forces, is calculated as a function of magnetic bead size (Rp) using Eq. 1–4 given in the
supplementary information. Brownianmotion of magnetic particles is not desirable because suchmotion would limit the bead transport. Results showed
that Brownian forces are not effective in our experiments with the current settings and dimensions of the setup. (d) Capillary pressure difference sustained
across the interface between mineral oil and PBS (dashed blue line), and magnetic forces (z 5 2 mm) per cross-section area of magnetic beads (solid red
line). (e) Simulation results of magnetic flux density (contours) and unit magnetic force along the horizontal plane (arrows) when a magnet moves
horizontally from left to right. Results are plotted for a range of time points (top-to-bottom, left-to-right). Full results are given in the supplementary
information. Dashed lines are the circular edges of the cylindrical magnet (top view).
www.nature.com/scientificreports
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Figure 4 | Clinical validation of micro-a-fluidic ELISA for CD41 T lymphocyte count. (a) and (b) Correlation of flow cytometry with micro-a-fluidic
ELISA for CD41 T lymphocyte count in 17 AIDS patient samples and 18 immunosuppressed patient samples, respectively. (c) and (d) Bland-Altman
analysis for the difference between flow cytometry and micro-a-fluidic ELISA for CD41 T lymphocyte count in 17 AIDS patient samples and 18
immunosuppressed patient samples, respectively. The 95% confidence interval on the mean is shown on the graphs. (e) Accuracy of CD41 T lymphocyte
micro-a-fluidic ELISA at the WHO clinical cutoff of 350 cells/mL for prioritizing ART. The samples were defined as positive once flow cytometry count
was below 350 cells/mL, otherwise negative.
www.nature.com/scientificreports
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Although shear stress can be significantly lowered at slow flow rates,
the assay time would be inevitably prolonged, which is not ideal for
POC testing. The micro-a-fluidic system was designed to accom-
modate POC testing with unique features such as a high degree of
automation, short assay turnaround time, and cell phone-based
imaging/readout. A brief comparison of these aspects among the
flow-based ELISA and the m-ELISA is presented in Supplementary
Table 1.
With its simplicity and rapidity, this micro-a-fluidic CD41 T
lymphocyte cell counting method can considerably facilitate the
expansion of ART in resource-constrained settings. In 2012, the
coverage of ART in low- and middle-income countries was approxi-
mately 34% despite free provision of antiretroviral drugs in most
developing countries1, due mainly to the lack of treatment monitor-
ing tools2. Until now, a variety of CD4 assays have been developed to
replace flow cytometry, i.e., the ‘‘gold standard rapid CD4 cell count
platform’’. On one hand, simplified flow cytometers such as
EasyCD412, CyFlow13 and Pan-leucogating14 have been developed
to reduce the instrumentation cost. Furthermore, manual CD4
assays such as Dynabeads and Cytosphere have been developed to
eliminate the need for instrumentation, which are more suitable for
de-centralized laboratories. On the other hand, microfluidic-based
CD4 cell counting technologies have moved rapidly forward, lever-
aging immune-based cell capture from whole blood in microchan-
nels10,15–17. Nevertheless, existing cell detection and counting
methods still have challenges such as high cost, technological com-
plexity, labor-intensiveness and most importantly inherent ‘‘liquid
flow’’ for POC testing.
In conclusion, a rapid, automated m-ELISA platform was
developed for POC testing in resource-constrained settings with a
demonstration of an unmet need for rapid CD41 T lymphocyte cell
count. This POC testing platform holds great potential to offer much
needed treatment monitoring services and significantly impacts the
scale-up of ART missioned by the WHO in resource-constrained
settings. In the future, this micro-a-fluidic platform can be broadly
applied to the detection of other types of cells for early diagnosis and/
or treatment monitoring of various diseases including cancer.
Methods
Device fabrication.Them-ELISA chips for CD41 cell countingwere assembled using
a non-lithographic technique as we previously reported18,19,21,22. To assemble this
device, poly(methyl methacrylate) (PMMA) (McMaster-Carr, Atlanta, GA) and
double-side adhesive film (DSA) (50 mm thick, iTapestore, Scotch Plains, NJ) were
cut using a LASER cutter (Versa Laser TM, Scottsdale AZ). The device dimensions
measured 43 mm 3 63 mm 3 6 mm. Three layers of PMMA of 2 different
thicknesses (1.5 mm and 3.175 mm) were used; the top and bottom layer of PMMA
were 1.5 mm thick and the middle layer of PMMA containing micro-chambers was
3.175 mm thick. The middle PMMA layer was designed to contain 5 circular
chambers (chambers i, ii and iii, as well as two wash chambers; chamber i having a
radius of 4.5 mm and the rest circular chambers having with a radius of 3.5 mm) to
contain ELISA reagents. These circular chambers were connected by 4 elliptical
chambers (with major and minor axes of 13.5 mm and 3.8 mm, respectively),
containing mineral oil (Sigma-Aldrich, St. Louis, MO) to separate ELISA reagents
(Fig. 1b). After chamber iii, there was another elliptical chamber (with major and
minor axes of 13.5 mm and 6.5 mm, respectively) containing mineral oil. The top
PMMA layer contained a single opening (0.4 mm radius) to load sample/reagent in
the circular chambers and two congruent openings for loading mineral oil in the
elliptical chambers, one to load and the other to allow for the escape of air. The bottom
PMMA layer had no openings. Two layers of DSA, with the same design as themiddle
PMMA layer, were used to assemble the micro-a-fluidic chips.
Functionalization ofmagnetic beads with primary anti-CD4 antibodies. Protein G
(PG) coated magnetic beads with a mean diameter of 2 mm (New England Biolabs,
Ipswich, MA) were used to serve as a solid phase to immobilize anti-CD4monoclonal
capture antibodies. In brief, the entire content of the Protein-G bead vial (2.16 3
10‘6 particles/ul, 1 mL) was removed by pipette to a 15-mL falcon tube (BD
Bioscience, Woburn, MA). 3 mL of Dulbecco’s phosphate buffered saline (DPBS)
(Invitrogen, Carlsbad, CA) was added on the PG beads. The falcon tube was applied
onto a magnetic stand for 1 minute to allow the PG beads to aggregate on the falcon
tube wall directly adjacent to the magnetic stand. The supernatant was removed by
pipetting and replaced with 4 mL DPBS, in order to wash the PG beads. After gentle
mixing for 1 min, the supernatant was once again removed and the washing step was
repeated 3 times. For CD41 cell capturing, 1 mL of 5 mg/mLmouse monoclonal anti-
CD4 antibody (Abcam, Cambridge, MA) was conjugated to the PG beads. The
antibody-magnetic bead solution was incubated overnight at 4uC on a rotator for
conjugation. After incubation, the PG beads were washed three times as mentioned
above to remove unbound anti-CD4 antibodies. The functionalized PG magnetic
beads were then blocked with 3% bovine serum albumin (Sigma-Aldrich, St. Louis,
MO) for 1 hour at room temperature. After another three-time wash using 1 mL of
DPBS, the magnetic beads were re-suspended in 1 mL of DPBS and stored at 4uC
prior to use.
HRP conjugation of secondary anti-CD3 antibodies. Rabbit polyclonal secondary
anti-CD3 antibody (0.2 mg/mL, Abcam, Cambridge, MA) was conjugated with
horseradish peroxidase (HRP) using an EasyLink HRP Conjugation Kit (3 3 100 mg
Biotin, Abcam, Cambridge, MA). According to the manufacturer’s instructions,
10 mL of EL-Modifier reagent was mixed gently with 100 ml of anti-CD3 antibody
(1580,000 dilution) in a 1.5 mL Eppendorf tube. After mixing, 100 mL of EL-HRP
mix was added. The resultant mixture was incubated overnight in dark at ambient
temperature. Following this, 10 mL of EL-Quencher reagent was added to stop the
conjugation process. The working concentration of anti-CD3 antibody was
experimentally determined to be 1580,000 diluted from the conjugated solution, at
which there was negligible color in the serum samples (serving as negative controls)
while still leading to strong color in positive standards.
Immunofluorescence staining of CD41 T lymphocytes captured on magnetic
beads. 100 mL of 1.5 mg/mL anti-CD4 Alexa Fluor 488 (BioLegend, San Diego, CA)
was added to 100 mL of whole blood (Massachusetts General Hospital, Boston, MA)
in an Eppendorf tube and incubated for 40 minutes in darkness at ambient
temperature. After incubation in order to wash away the excess antibody, 200 mL of
0.05% tween-20 washing buffer (DPBST), was added. The resultant solution was
mixed gently and centrifuged for 10 seconds at 6000 RPM (Labnet Spectrafuge Mini
Centrifuge, Korea). The supernatant was then removed, and the pelleted cells were
washed twice through the addition of DPBS and subsequent removal of supernatant.
Next, 100 mL of 6 mg/mL Anti-CD3 Alexa Fluor 647 was added to the Eppendorf
tube, and incubated for 40 minutes in darkness at ambient temperature. Again, the
washing step was preformed 3 times as mentioned above. Afterwards, 20 mL of anti-
CD4 antibody coated magnetic beads were added and incubated for 10 minutes at
room temperature in darkness. After incubation,magnetic beadswith captured CD41
cells were collected using a magnetic stand and were washed with 200 mL of DPBST
twice. 10 mL of DPBS was added to re-suspend the magnetic beads with captured
CD41 cells and 1 mL of the mixture was mounted to a glass slide for fluorescence
imaging. Magnetic beads conjugated with CD41 T lymphocytes were mounted to a
glass slide for fluorescence and bright-field imaging.
Scanning ElectronMicroscopy (SEM) Imaging.The cells were fixed and dehydrated
using ethanol solution. The cells were then dried of ethanol on coverslips and
mounted onto aluminum SEM sample holders (Ted Pella Inc., Redding, CA) using
conductive carbon tape (Ted Pella Inc., Redding, CA). The mounted samples were
coated with Platinum/Palladium at 40 mA for 90 seconds (Cressington Scientific
Instruments Ltd., Watford, England) in an Argon gas purged chamber. After coating,
samples were imaged using field emission SEM (Ultra 55, Carl Zeiss Micro Imaging
LLC, Thornwood, NY) under high vacuummode using in-lens detector. The samples
were imaged at 10,0003–30,0003 magnifications at 5 kV accelerating voltage and
,5 mm working distance.
Reagent loading. HRP-conjugated anti-CD3 rabbit polyclonal antibody (15800,000
dilution), one-Step ultra 3,39,5,59-tetramethylbenzidine (TMB) (Thermo Scientific
Inc., Waltham, MA), and 100 mL of PBST was pipetted into chambers ii, iii, and the
unlabelled smaller circular chambers, respectively (Fig. 1b). These small volumes of
reagents filled up the circular chamber volume without leaking into adjacent elliptical
chambers due to high surface tension from the interface between the liquid reagents
and the inner surface of the micro-a-fluidic chip. After these reagents were input,
approximately 213 mL of mineral oil was injected to fill the last elliptical chamber.
And 125 mL of mineral oil was loaded into other elliptical chambers, except for the
first elliptical chamber (between chamber i and the first wash chamber). Next, 25 mL
of themagnetic beads conjugatedwithmousemonoclonal anti-CD4 capture antibody
and 10 mL of blood sample was loaded into the sample chamber i. DPBST was then
added to fill the remaining volume of chamber i. Lastly, 125 mL of mineral oil was
loaded into the remaining elliptical chamber.
m-ELISA by magnetic actuation. Magnetic force was utilized to mechanically
actuate the movement of magnetic beads through all the chambers by use of a
magnetic stage that was fully automated via a program and the total assay time was 9
minutes. The loaded micro-a-fluidic chip was placed in an appropriate slot of the
portable instrument (Supplementary Fig. 2). The actuation of permanentmagnet was
automated (Video 1, Supplementary File 2) using an in-house developed program.
Upon the placement of the micro-a-fluidic chip on the instrument, a permanent
magnet (1/40 dia. 3 10 thick, K&J Magnetics, Inc.) underneath chamber i settled the
magnetic beads with captured CD41 T lymphocytes via antibody-antigen interaction.
The PG magnetic beads with captured CD41 T lymphocytes were moved to the next
circular chamber, crossing the oil barrier in the elliptical chamber, via the NdFeB
magnet placed on a linear X-direction stage. In this chamber, bead washing was
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performed with wash buffer by actuating the conjugated beads back and forth within
the wash chamber. The back and forth motion of the magnet resulted in collection of
residual magnetic beads left in the previous elliptical oil chamber. After mixing for 1
minute in thewash chamber, the beadswere further actuated to chamber ii containing
theHRP-conjugated anti-CD3 secondary antibody.Whilemixing for 1minute in this
chamber, captured CD41 T lymphocytes interacted with the anti-CD3 antibody,
forming an anti-CD4 antibody/CD41 T lymphocyte/anti-CD3 antibody sandwich
structure. The magnetic beads with the immune complex were then moved to the
second wash chamber. Following another washing step, the magnetic beads with the
immune complex weremoved to chamber iii containing TMB and accordingly mixed
for 6 minutes. Due to the presence of HRP-antibody captured on the magnetic beads,
the substrate TMB was digested and a blue color was developed. Thus, the total assay
time was 9 minutes. The magnetic beads were removed from chamber iii into the last
elliptical oil chamber and actuated back and forth for an additional minute to attract
and remove any residual beads left in chamber iii. While bead mixing, the blue
solution in chamber iii was mixed manually using a pipet to achieve a homogeneous
color density.
Imaging and data analysis using a cell phone. The m-ELISA-based chip with
homogeneous blue color in chamber iii was immediately placed onto a white LED-
illuminated translucent white acrylic plexiglass (McMaster-Carr, Atlanta, GA) sheet
inside a black plastic box (Supplementary Fig. 3). The black box was used to provide
an isolated light environment, where light variation in ambient environment is
reduced. The internal LED lighting setup was to achieve even background during
imaging. On top of the black box, there was an opening where a cell phone with a
built-in camera was used to image the color intensity. To facilitate image processing,
we developed a desktop application that automatically selects the region for
colorimetric analysis, calculates R values and normalizes R values according to the
background in a batch-processing format (Supplementary Fig. 4). The normalized
red pixel value of negative control (plasma) as a result of 1580,000 HRP antibody was
used as a basis to determine the sensitivity (mean62 standard deviation). In addition,
we developed a mobile application that has the same analysis functionality as the
desktop application but also constructs the standard curve and reports the
quantification results (Supplementary Fig. 5).
Flow cytometry. The CD4 cell count of clinical samples was measured using the gold
standard – flow cytometry. Before measurement, the FACSCalibur system (Beckton
Dickinson, San Jose, CA) was calibrated using Becton Dickinson BD CaliBRITETM
Beads. Becton Dickinson Multi-Check CD4 Low Control and Multi-Check Control
were used in parallel with clinical samples to ensure accuracy and reliability of flow
cytometry. For eachmeasurement, 20 mL of antibodymixture anti-CD3/CD8/CD45/
CD4 antibodies and 50 mL blood or control were added to TrucountTM Tubes. After
incubation for 15 minutes at room temperature, red blood cells were lysed in 450 mL
of 13 FACS Lysing Solution. After another 15 min-incubation, the mixture was
loaded to the flow cytometer for CD4 cell count using Becton Dickinson MultiSETTM
software. For assessing the capture efficiency of CD4 T1 T lymphocytes to magnetic
beads, it was calculated based on the following equation.
Capture ef f iciency%~
Number of cells inwhole blood{Number of cells in supernatent
Number of cells inwhole blood
|100%
Clinical testing.With the approval of the Institutional Review Board (IRB) (protocol:
2009P0001790), 17 discarded anonymous and de-identified HIV-infected whole
blood patient samples were collected from the Massachusetts General Hospital
(MGH). In addition, 18 discarded immunosuppressed patient samples were tested
using the micro-a-fluidic CD4 assay. These clinical samples were tested in duplicates
using the micro-a-fluidic ELISA. In parallel, a whole blood sample from a healthy
blood donor was serially diluted and tested (including undiluted, 153, 159, 1527, and
1581) to construct a standard curve for cell quantification. The CD4 cell count of the
undiluted whole blood sample was analyzed using flow cytometry. The normalized
red pixel numbers of the clinical samples were interpolated with the logarithmic fit
equation of the standard curve, and CD41 T lymphocyte count was calculated.
Statistics analysis. In this study, we used MedCalc to calculate the correlation
coefficient of m-ELISA and flow cytometry for CD4 cell count. Altman-Bland
analysis was also performed to assess the accuracy of CD4 cell quantification by the
micro-a-fluidics ELISA compared to flow cytometry. The utility of micro-a-fluidic
CD4 cell count for determining treatment failure or initiating antiretroviral treatment
was plotted using both AIDS and immunosuppressed populations.
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